Custom-Made vaccine takes on kidney cancer in early trial
NCT ID NCT02950766
First seen Feb 03, 2026 · Last updated May 14, 2026 · Updated 14 times
Summary
This early-phase study tests a personalized vaccine made from each patient's unique tumor mutations, combined with the immunotherapy drug ipilimumab, for people with high-risk kidney cancer. The goal is to see if the treatment is safe and can boost the immune system to fight the cancer. Nineteen participants who had their kidney cancer surgically removed are enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
Conditions
Explore the condition pages connected to this study.